Abbott (ABT) to Acquire Exact Sciences — $20B Notes, Cash

Abbott announced on 2026-03-09 that it intends to acquire Exact Sciences, with the transaction to be funded by $20 billion in notes and the use of cash. The disclosed funding mix identifies a significant debt instrument component (the $20 billion of notes) alongside cash resources. No other transaction terms, purchase price allocation, or closing timeline are provided in the materials supplied here. The funding approach is explicitly debt-plus-cash. Investors should note that a large notes issuance implies an increase in funded indebtedness if and when those notes are issued and outstanding; the precise impact on Abbott’s balance sheet, leverage ratios, and interest expense depends on final deal terms, timing and any accompanying financing or refinancing actions that have not been disclosed in this input.

Abbott’s public filings and profile indicate a corporate emphasis on growth through acquisitions and a focus on higher-growth areas such as Diagnostics, Diabetes Care (FreeStyle Libre), and Structural Heart. The company describes four reportable businesses — Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices — and has previously indicated acquisition activity as a component of growth strategy. Given that context (as provided), the Exact Sciences acquisition is consistent with Abbott’s stated approach of using strategic deals to expand and strengthen its portfolio. Abbott’s diagnostics and device capabilities and its stated R&D/innovation priorities (molecular diagnostics platforms, point-of-care testing, and other technologies identified in its disclosures) provide a factual backdrop for why management might pursue deals in adjacent diagnostics or screening areas; however, no specific strategic rationale for this Exact Sciences transaction is supplied in the materials provided.

Recent filings show Abbott generated $32,869 million of revenue for the nine months ended September 30, 2025, with a geographic split of U.S. $12,743 million (38.8%) and International $20,126 million (61.2%). Segment-level nine-month figures include Diagnostic Products ($11,369 million), Medical Devices partial totals (U.S. $5,448 million for nine months with Diabetes Care ~$2,057 million), Nutritional Products (~$15,712 million partial), and Established Pharmaceutical Products (international $4,154 million for emerging markets/other). Full-year 2025 segment totals are not provided in the source excerpt. These scale metrics underscore Abbott’s large international footprint and diversified business mix. Any material acquisition funded by substantial notes and cash will interact with Abbott’s existing capital structure and the company’s exposure to macroeconomic risks such as currency fluctuations and inflationary pressures, which are highlighted in its risk disclosures.

Abbot’s filed risk factors include regulatory risks (FDA approvals/delays and changing reimbursement), legal and remediation exposures, macroeconomic factors (currency, supply chain, inflation), competition and execution risk (including product obsolescence and generic substitution), and cybersecurity threats. These existing risk categories will be relevant to assessing the combined company post-transaction and to evaluating integration execution risk. Additionally, Abbott’s own governance and strategic disclosures note that the company’s competitive advantages are execution-based rather than a durable structural economic moat. Management has identified patents and technologies of material importance across diagnostics and devices, but no single patent or trademark is described as material to the business as a whole. Investors should therefore consider the acquisition within the framework of an execution-led strategy rather than relying on entrenched structural barriers.